BOZEN, Italy, July 13 -- Health Robotics today announced that it has decided to
complement its successful indirect channel strategies with direct investments in
local infrastructure at a few territories where a couple of Health
Robotics’ distributors have been negatively affected by a number of
factors, such as the global economic crisis, a distributor’s litigation
with investors, and some financial difficulties supporting our customers. Some
of these new channel strategy decisions have followed a direct channel operation
model, while others have taken the form of JV (joint venture) channel
strategies.

As part of this new strategy, Health Robotics will shortly make a series of
detailed announcements on steps it recently undertook, for instance entering
direct operations in Germany with the execution of a contract with
Charite-Universitatsmedizin Berlin; plans to establish JVs in North America and
South East Asia; expanding its indirect channel partner line-up in Taiwan and
Oceania; and if necessary, terminating for cause some of Health Robotics’
indirect distribution agreements with companies that might be unwilling or
unable to adequately support our customers.

This key milestone to diversify and expand beyond our traditional indirect
channels demonstrates the company’s maturity and its financial stability
in this global economic crisis, already proven with the recent release of 2008
Financial Results. While Health Robotics continues to be fully committed to its
indirect channel partners, it has become necessary to take this step in order to
protect some of our customers’ investments in Health Robotics’
technology and insulate our customers from the negative effects that the
economic crisis has had on some of our distributors and the pending litigation
between one of our distributors and its capital founders. Without this swift
intervention, some of these factors could potentially have had a serious
negative impact of the on-time delivery of our products to customers, something
we are not willing to tolerate. At Health Robotics, our customers’ best
interests shall always take precedence over other marketing or sales channels
factors or considerations, stated Werner Rainer, CEO of Health Robotics.

About Health Robotics:

Health Robotics is the global leading supplier of life-critical intra-venous
medication preparation, compounding, and dispensing Robots, with fifty-times
more units sold that all of its competitors combined, and providing healthcare
facilities in four continents with robotics technology and software automation
solutions. The world-leading solutions CytoCare [hazardous IVs], i.v.STATION
[non-hazardous IVs], and the current development of TPNstation [parenteral
nutrition] have and will greatly contribute to ease global hospitals’
growing pressures to improve patient safety through the effective and efficient
production of sterile, accurate, and ready-to-administer IVs, to eliminate
life-threatening drug-exchange errors, to decrease other medication errors and
contamination risks, and to work more efficiently, increase throughput, reduce
waste, and contain costs.

For additional information, please contact: Health Robotics Gaspar G. DeViedma
Europe: +39-346-963-4934 USA: +1-609-980-7976
gaspar.deviedma@health-robotics.com

SOURCE: Health Robotics

Health Robotics: Gaspar G. DeViedma, Europe: +39-346-963-4934, USA:
+1-609-980-7976, gaspar.deviedma@health-robotics.com